Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

p>

  • Top line results from the phase II trial in healthy adults with our trivalent seasonal flu vaccine candidate;
  • Preclinical results of studies with vaccine candidates against the Respiratory Syncitial Virus (RSV);
  • Commencement of operations of the joint venture with Cadila Pharmaceuticals Ltd in India; and,
  • Initiation of a Phase II clinical study of our trivalent seasonal flu vaccine in older adults.

2009 Financial Results

Revenue from operations for the first quarter ended March 31, 2009 was $0.02 million compared to $0.5 million for the same period in 2008, a net decrease of $0.4 million due to the completion of a government contract in the first quarter of 2009.

Research and development costs for the first quarter of 2009 were $4.3 million compared to $4.4 million in the first quarter of 2008. The decrease was due to a $0.2 million decrease in employee costs and a $0.1 million decrease associated with the closing of the Taft Court facility in October 2008 when the Company consolidated its operations into the Belward Campus facility. These decreases were partially offset by an increase in $0.1 million in outside testing costs associated with the continuing clinical trials, preclinical testing, process development, manufacturing and quality related programs and a $0.1 million increase in facility costs.

General and administrative costs were $2.9 million in the first quarter of 2009 as compared to $3.2 million in the first quarter of 2008. The $0.3 million decrease was due to a decrease in employee costs of $0.1 million, a decrease in facility costs associated with general and administrative functions of $0.1 million, and a decrease of $0.2 million in charges to the allowance established for two notes receivable from former directors. The Company determined that the notes receivable
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... PA (PRWEB) September 02, 2014 ... a new highly efficient, cost effective approach to ... Patent No. 8,820,265 by the U.S. Patent and ... to Opertech. , “Opertech’s taste evaluation ... the first automated high throughput system for rapid ...
(Date:9/2/2014)... Calif. , Sept. 2, 2014  Xencor, ... biopharmaceutical company developing engineered monoclonal antibodies for the ... and cancer, today announced the appointment of ... development and the appointment of Lloyd Rowland ... general counsel. "Debra,s expertise in ...
(Date:9/2/2014)... , Sept. 2, 2014  Synthetic Biologics, Inc. ... biologic and drug candidates targeting specific pathogens that ... results from its final preclinical toxicology study of ... guidance, this bridging study was required to move ... to prevent the devastating effects of Clostridium ...
(Date:9/2/2014)... Mount, NC (PRWEB) September 02, 2014 ... establishment of its 11th clinical research site: PMG Research ... assumed ownership and operation of the clinical research department ... further expanding PMG’s presence in eastern North Carolina. This ... patients. For the patients in Rocky Mount and the ...
Breaking Biology Technology:Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3
... German . , They have been used as ... they are making rapid inroads in high performance applications: CMOS ... and digital cameras. The automotive industry, for instance, has discovered ... them in driver assistance systems from parking aids and ...
... Palatin Technologies, Inc. (NYSE Amex: PTN ) today announced ... of its common stock and warrants to purchase common stock in ... and there can be no assurance as to whether or when ... or terms of the offering. Roth Capital Partners is ...
... 23, 2011 Scarguard Labs, LLC, a closely held ... other dermatological problems through the use of multi-technology drugs ... that they have received approval from Health Canada to ... "We are very pleased to gain approval for ...
Cached Biology Technology:UV-transparent coating for image sensors 2Palatin Technologies, Inc. Announces Proposed Public Offering of Common Stock and Warrants 2Palatin Technologies, Inc. Announces Proposed Public Offering of Common Stock and Warrants 3
(Date:9/2/2014)... through a U.S. suburb , Observations and mapping ... the hours and days after the August 24 earthquake ... earthquake caused so much damage in the region, according ... by the American Geophysical Union. , ... Places to Direct Our Curiosity , Selecting where ...
(Date:9/2/2014)... Human Genetics (ASHG) and the National Human Genome ... of Health, have named Katherine D. Blizinsky, PhD, ... newest ASHG/NHGRI Genetics and Public Policy Fellow. The ... Public Policy Fellowship is intended to help early-career ... research policy at a national level. Fellows in ...
(Date:9/2/2014)... team of University of Maryland physicists has published ... say make possible new nanostructures and nanotechnologies with ... quantum computing advances to new sensor development. , ... Nature Communications the Maryland scientists, primary discovery ... nanostructures that uses a connector, or "intermedium," nanoparticle ...
Breaking Biology News(10 mins):This week From AGU: California earthquake, future Mars rovers, models underestimate ozone 2ASHG and NHGRI award genetics and public policy fellowship 2New synthesis method may shape future of nanostructures, clean energy 2New synthesis method may shape future of nanostructures, clean energy 3
... June, 2010) SAGE, the world,s fifth leading independent ... the Bulletin of the Atomic Scientists from September ... other experts who had created the atomic bomb as part ... threats to the survival and development of humanity from nuclear ...
... research led by the University of Leicester and published in ... first time the mechanism by which memories are formed. ... found one of the key proteins involved in the process ... to impact drug design to treat Alzheimer,s disease. The ...
... the hon-shimeji mushroom is a delicacy costing up to SEK 8,000 ... of Gothenburg, Sweden, has discovered that this tasty fungus also grows ... of interest in Sweden, and definitely in Japan once these discoveries ... Lyophyllum is a family of many different species ...
Cached Biology News:SAGE to publish the Bulletin of the Atomic Scientists 2Memories are made of this 2Japanese gourmet mushroom found in Sweden 2Japanese gourmet mushroom found in Sweden 3
11-keto Testosterone EIA Antiserum hormones steroids antisera antiserum eias enzyme immunoassays reagents 11-keto-testosterone...
... (phospho S207) ( Abpromise for ... Antigen: Synthetic phosphopeptide derived from ... of Serine 207 (V-D-S P -V-A). ... 5608 Swiss ...
Anti-human L-Ficolin, Clone GN4, Monoclonal Antibody...
14-3-3 tau Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: